Drug maker, Wockhardt shall soon exit from corporate debt restructuring (CDR) as bankers believe that the company is doing exceedingly well, as mentioned in some media report. A major lender to the company’s debt restructuring arrangement includes State Bank of India.
The pharmaceutical company got CDR lifeline back in 2009 and currently owes a reimbursement of Rs 160 crore to bankers. Putting an end to a two-year-long legal conflict between a group of anguished investors and the troubled drug maker, the Bombay high court on October 11, 2011, directed Wockhardt to clear all dues to its bondholders by August 2012. The court has set a time frame for the repayment of Rs417.47 crore dues, including interest.
Wockhardt reported net loss of Rs 68.64 crore for the quarter ended March 31, 2012, against net profit of Rs 32.25 crore for the corresponding period last fiscal. However, total income increased by 68.90% at Rs 722.93 crore during the quarter under review from Rs 428.03 crore in the year-ago period.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1824.00 |
| Dr. Reddys Lab | 1267.80 |
| Cipla | 1355.80 |
| Zydus Lifesciences | 1074.30 |
| Lupin | 2327.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: